Gadolinium Campaign Details

Prices listed are the current retail value and may be higher or lower based on availability, size of budget, demand, volatility and additional filters.

  • Gadolinium lead
    Call for pricing
  • Gadolinium signed
    Call for pricing

Gadolinium Criteria

  • Claimant had a series of MRIs or MRAs w/ contrast
  • Series of MRIs/MRAs occurred no earlier than 2010
  • Claimant suffered any of the following w/in 2 months of MRI/MRA
    • Brain Fog
    • Cognitive Impairment
    • Chronic headaches/migraines
    • Nausea/vomiting
    • Significant burning, sharp, or cutting body pain
    • Pins and needles sensation
    • Tissue burning sensation
    • Deep Bone and Joint pain
    • Loss of mobility
    • Thickening/darkening of skin
    • Shortening of muscles/tendons
    • Gadolinium Storage Condition diagnosis
    • Gadolinium Deposition Disease diagnosis
  • Claimant was NOT suffering from their chosen injuries BEFORE the series of MRIs/MRAs
  • Disqualify if Diagnosed and Treated prior for any of the following
    • Multiple Sclerosis (MS)
    • Kidney/renal failure
    • Peripheral Neuropathy
    • Meningitis
  • Not Represented or Previously Declined

Gadolinium Background Information

Claims of Note

In November 2017 Chuck Norris and his wife filed suit against 11 pharmaceutical manufacturers and distributors over her being poisoned by gadolinium contrast agents (GCBA) she was injected with during MRI scans. No MDL has been formed as of yet, but Gadolinium Toxicity has rapidly become one of the most sought after claimants over the past six months.

Issues/ injuries

Gadolinium is used in contrast dyes during magnetic resonance imaging (MRI), used in approximately 30% of scans, and magnetic resonance angiography (MRA). Patients with pre-existing kidney conditions who receive a gadolinium-containing contrast agent during these scans are at risk for developing nephrogenic systemic fibrosis (MDL 1909 – resolved). New concerns regarding gadolinium is something known as gadolinium retention, gadolinium deposition disease, or gadolinium storage condition.

FDA Warning

September 2017, the Medical Imaging Drugs Advisory Committee (MIDAC) of the US Food and Drug Administration voted overwhelmingly to add more warnings to gadolinium-based contrast agents. These warnings will include the risk of gadolinium retention in a patient’s body, including the brain.


GE Healthcare, Bracco Diagnostics, Mallinckrodt Inc, Berlex Labs, among others

MDL #2868

On October 10, 2018 JPML panel denied the motion to centralize claims. They note, in part, that the vast majority of claims filed are all represented by a single law firm or working as co-counsel with another firm related to the action. A new petition is likely to be filed in the coming year as more firms file suit.

Gadolinium-based contrast agents approved by the FDA

  • gadoterate (Dotarem by Guerbet LLC)
  • gadodiamide (Omniscan by GE Healthcare)
  • gadobenate (MultiHance by Bracco)
  • gadopentetate (Magnevist by Bayer)
  • gadoteridol (ProHance by Bracco)
  • gadofosveset (Ablavar, formerly Vasovist, by Bayer)
  • gadoversetamide (OptiMARK by Guerbet)
  • gadoxetate (Eovist by Bayer)
  • gadobutrol (Gadavist by Bayer)


We welcome you to contact Mass Torts USA for more information
about our products and services.